olmutinib

Ligand id: 9196

Name: olmutinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 110.86
Molecular weight 486.18
XLogP 4.56
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (South Korea (2016))
IUPAC Name
N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
International Nonproprietary Names
INN number INN
10093 olmutinib
Synonyms
BI-1482694 | Example 1 [US20130116213] | HM-61713 | HM61713
Database Links
CAS Registry No. 1353550-13-6 (source: WHO INN record)
GtoPdb PubChem SID 315661275
PubChem CID 54758501
Search Google for chemical match using the InChIKey FDMQDKQUTRLUBU-UHFFFAOYSA-N
Search Google for chemicals with the same backbone FDMQDKQUTRLUBU
Search PubMed clinical trials olmutinib
Search PubMed titles olmutinib
Search PubMed titles/abstracts olmutinib
Search UniChem for chemical match using the InChIKey FDMQDKQUTRLUBU-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone FDMQDKQUTRLUBU
Comments
Olmutinib from Hanmi Pharmaceutical, approved in South Korea for lung cancer, targets mutant epidermal growth factor receptor (EGFR) selectively over wild-type. It is reported as an oral, third-generation EGFR tyrosine kinase inhibitor (binding covalently), however there is no published, peer-reviewed data to confirm this. The potential for using third-generation EGFR inhibitors in EGFR-mutated non-small lung cancer is reviewed by Russo et al. (2017) [7]. Olmutinib is claimed in patent WO2011162515 [1]. Full text descriptions and structure images are available in US20130116213 [3], where it is identified as Example 1 (N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide). Note we updated this entry in Nov 2016 with the removal of the incorrect synonyms HM-71224 and LY3337641 which refer to a blinded Hanmi BTK inhibitor [4].